The novel prolintane analogs described here may serve as a valuable starting point for the development of new candidates for ADHD treatment, as they were inactive as releasers at DAT and NET, suggesting a low potential for abuse and cardiovascular stimulation, and they showed lower DAT/SERT ratios. The gene discussed is SLC6A4; the disease is attention deficit-hyperactivity disorder.